Endogena Therapeutics is a clinical-stage biotech company that discovers and develops first-in-class endogenous regenerative medicines to repair and regenerate tissues and organs. 

Endogena Therapeutics’ approach to endogenous regenerative medicine will result in a novel treatment paradigm for common degenerative diseases that are becoming more prevalent due to demographic changes.

Endogena Therapeutics is focusing its drug discovery and development efforts on indications with high unmet medical needs.

Recent discoveries in stem cell biology together with technological advances for phenotypic, functional screening, have unlocked our ability to harness the potential of adult stem- and progenitor cells. Our novel drug discovery approach is based on the concept of selective regulation of these endogenous cells for controlled tissue repair by small molecules.

Endogena Therapeutics Executive Team

• Matthias Steger, CEO and Founder

• Moreno Menghini, Chief Medical Officer

• Daphna Mokady, Chief Scientific Officer

• Susanne Raab, Chief Development Officer

• Sven Weiler, Vice President Medicinal Chemistry

• Michael Lai, Medical Director Clinical Development

Endogena Therapeutics Board of Directors

• Matthias Steger

• Elona Baum

• Dan Zabrowski

• Aaron Weaver